| Tarantini, Giuseppe |
| Recruiting | 3 | 430 | Europe | Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses | Fondazione Italiana Linfomi ONLUS, GRADE Onlus | Diffuse Large B-Cell Lymphoma, Elderly Patients | 09/25 | 09/30 | | |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
| Terminated | 2 | 37 | Europe | Copanlisib, ALIQOPA | Fondazione Italiana Linfomi - ETS | Diffuse Large B-cell Lymphoma | 12/24 | 12/24 | | |
| Active, not recruiting | N/A | 1500 | Europe | Mitraclip | IRCCS Policlinico S. Donato | Mitral Regurgitation | 02/21 | 09/25 | | |
| Recruiting | N/A | 343 | Europe, RoW | Questionnaire | Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC | Acute Myeloid Leukemia | 06/21 | 12/22 | | |
CAvEAT, NCT04647864: The Coronary AccEss After Tavi Registry - A Multicenter Prospective Registry for the Coronary Access After TAVI |
|
|
| Recruiting | N/A | 600 | Europe | Transcatheter Aortic Valve Implantation, Transcatheter Aortic Valve Replacement, Percutaneous aortic valve replacement (PAVR), Percutaneous aortic valve implantation (PAVI) | University of Padova, Fondazione GISE Onlus | Aortic Valve Disease | 06/22 | 12/22 | | |
NCT04581187: An Online-platform to Improve Patient-centered Care During the COVID-19 Pandemic: a GIMEMA Surveillance Program in Hematologic Malignancies |
|
|
| Recruiting | N/A | 400 | Europe | Quality of life assessment | Gruppo Italiano Malattie EMatologiche dell'Adulto | Hematologic Malignancies | 12/22 | 12/24 | | |
EUROSHOCK, NCT03813134: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock |
|
|
| Recruiting | N/A | 428 | Europe | Percutaneous coronary intervention (PCI), Pharmacological Support, VA-ECMO, Veno-Arterial Extra Corporeal Membrane Oxygenation. | University of Leicester, European Commission, University of Glasgow, KU Leuven, University of East Anglia, Deutsches Herzzentrum Muenchen, A.O. Ospedale Papa Giovanni XXIII, Chalice Medical Ltd, Ludwig-Maximilians - University of Munich, University of Tromso, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Paula Stradina Liniska Universitates, Accelopment AG, Universiteit Antwerpen, Cardiovascular European Research Centre (CERC) | Cardiogenic Shock | 03/23 | 02/24 | | |
| Active, not recruiting | N/A | 418 | Europe, Canada, US, RoW | SELUTION SLR™ DEB, Control | M.A. Med Alliance S.A., Iqvia Pty Ltd, Cordis Corporation | Coronary Restenosis | 07/25 | 08/29 | | |
NCT05844969: Circle Method Observational Project - Non-interventional, Retrospective, Multicenter Data Collection |
|
|
| Not yet recruiting | N/A | 60 | Europe | | Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences | Aortic Stenosis With Bicuspid Valve | 08/25 | 08/25 | | |
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) |
|
|
| Recruiting | N/A | 200 | Europe | | Incyte Biosciences Italy S.r.l, Advice Pharma Group srl | DLBCL - Diffuse Large B Cell Lymphoma | 06/25 | 06/27 | | |
TARGET FIRST, NCT04753749 / 2020-005933-34: Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy |
|
|
| Active, not recruiting | N/A | 2248 | Europe | Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin), Standard DAPT | MicroPort CRM, European Cardiovascular Research Center | Myocardial Infarction, Acute, Coronary Artery Disease | 04/25 | 04/25 | | |
| Recruiting | N/A | 590 | Europe, RoW | Navitor Transcatheter Aortic Valve and FlexNav Delivery System | Abbott Medical Devices | Symptomatic Severe Aortic Stenosis | 06/25 | 02/36 | | |
| Recruiting | N/A | 150 | Europe, Canada, RoW | Elective redo transcatheter aortic valve implantation (redo-TAVI), redo-TAVI, redo-TAVR, Valve-in-Valve (ViV), TAV-in-TAV, TAVR-in-TAVR, Revalve | Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences | Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction, Prosthesis Failure | 09/25 | 12/26 | | |
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis |
|
|
| Recruiting | N/A | 400 | Europe | Treatment for clinical practise | Fondazione Italiana Linfomi ONLUS | Classical Hodgkin Lymphoma | 01/26 | 01/26 | | |
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors |
|
|
| Recruiting | N/A | 552 | Europe | Lifestyles Implemented-Survivorship Care Plan (LS-SCP) | Fondazione Italiana Linfomi - ETS | Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) | 02/26 | 02/26 | | |
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice |
|
|
| Recruiting | N/A | 1500 | Europe | "novel" MAB (alone or in combination) | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Non-Hodgkin Lymphoma, B-cell | 10/38 | 10/38 | | |
